Candel Therapeutics (CADL) to Announce Earnings on Thursday

by · The Markets Daily

Candel Therapeutics (NASDAQ:CADL – Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.22) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Price Performance

CADL stock opened at $10.65 on Wednesday. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $11.36. The stock’s fifty day simple moving average is $9.53 and its 200-day simple moving average is $7.30. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $780.33 million, a price-to-earnings ratio of -10.87 and a beta of -0.51.

Insider Transactions at Candel Therapeutics

In other news, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the transaction, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This trade represents a 23.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the completion of the transaction, the chief technology officer directly owned 83,865 shares in the company, valued at $840,327.30. This represents a 7.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is currently owned by insiders.

Institutional Trading of Candel Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CADL. Moneta Group Investment Advisors LLC increased its holdings in Candel Therapeutics by 4.9% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock valued at $240,000 after purchasing an additional 2,000 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Candel Therapeutics by 29.0% during the fourth quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock worth $85,000 after purchasing an additional 3,380 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Candel Therapeutics by 25.5% during the fourth quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock worth $110,000 after purchasing an additional 3,955 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after buying an additional 4,439 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Candel Therapeutics by 37.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock worth $95,000 after buying an additional 4,583 shares during the period. Institutional investors and hedge funds own 13.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CADL. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Candel Therapeutics in a research report on Wednesday, July 29th. Finally, Cantor Fitzgerald initiated coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating for the company. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Candel Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $18.57.

Get Our Latest Research Report on Candel Therapeutics

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

Featured Stories